Bio&Bio’s toxic shock syndrome vaccine research concluded
Positive results showed the TSST-1 vaccine is effective with immunisation lasting for at least two years
Read More
Tag: Bio&Bio
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
